US2013130979A1PendingUtilityA1

Peptides that bind to the erythropoietin receptor

57
Assignee: AFFYMAX INCPriority: May 12, 2003Filed: Oct 18, 2012Published: May 23, 2013
Est. expiryMay 12, 2023(expired)· nominal 20-yr term from priority
Inventors:Christopher P. HolmesQun YinGuy LalondePeter J. SchatzDavid TumeltyBalu PalaniGenet Zemede
A61P 37/02A61P 9/00A61P 7/08A61P 7/06A61P 7/00A61P 35/00A61P 9/10A61P 7/04A61P 31/18A61P 43/00A61P 25/00A61P 29/00A61P 13/12A61P 17/02A61P 19/02A61P 1/00A61P 15/00C07K 7/08A61K 38/16A61K 38/10C07K 14/001C07K 14/505A61K 38/00C07K 14/00
57
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, are also provided.

Claims

exact text as granted — not AI-modified
1 . A method for treating a patient, comprising administering to a patient having a disorder characterized by a deficiency of erythropoietin or a low or defective red blood cell population, a therapeutically effective amount of a peptide comprising about 17 to about 40 amino acid residues in length and comprising the amino acid sequence:
   LYACHX 0 GPITX 1 VCQPLR(SEQ ID NO:1)   
       wherein X 0  is a residue selected from the group consisting of methionine (M) and homoserine methylether (Hsm), and X 1  is a residue selected from tryptophan (W), 1-naphthylalanine (1-nal), and 2-naphthylalanine (2-nal). 
     
     
         2 - 29 . (canceled)

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.